JP2003535015A - 調整された出血を伴うプロゲスチン治療 - Google Patents

調整された出血を伴うプロゲスチン治療

Info

Publication number
JP2003535015A
JP2003535015A JP2000516679A JP2000516679A JP2003535015A JP 2003535015 A JP2003535015 A JP 2003535015A JP 2000516679 A JP2000516679 A JP 2000516679A JP 2000516679 A JP2000516679 A JP 2000516679A JP 2003535015 A JP2003535015 A JP 2003535015A
Authority
JP
Japan
Prior art keywords
progestin
progesterone
water
bleeding
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000516679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003535015A5 (cg-RX-API-DMAC7.html
Inventor
ドミニク・ドゥ・ジーグレ
ウィリアム・ジ・ボローニャ
ハワード・ジェイ・レバイン
Original Assignee
コロンビア・ラボラトリーズ・(バミューダ)・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コロンビア・ラボラトリーズ・(バミューダ)・リミテッド filed Critical コロンビア・ラボラトリーズ・(バミューダ)・リミテッド
Publication of JP2003535015A publication Critical patent/JP2003535015A/ja
Publication of JP2003535015A5 publication Critical patent/JP2003535015A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2000516679A 1997-10-21 1998-10-21 調整された出血を伴うプロゲスチン治療 Pending JP2003535015A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6348597P 1997-10-21 1997-10-21
US60/063,485 1997-10-21
US09/170,326 1998-10-13
US09/170,326 US6306914B1 (en) 1997-10-21 1998-10-13 Progestin therapy for maintaining amenorrhea
PCT/US1998/022169 WO1999020282A1 (en) 1997-10-21 1998-10-21 Progestin therapy with controlled bleeding

Publications (2)

Publication Number Publication Date
JP2003535015A true JP2003535015A (ja) 2003-11-25
JP2003535015A5 JP2003535015A5 (cg-RX-API-DMAC7.html) 2005-12-22

Family

ID=26743461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000516679A Pending JP2003535015A (ja) 1997-10-21 1998-10-21 調整された出血を伴うプロゲスチン治療

Country Status (19)

Country Link
US (3) US6306914B1 (cg-RX-API-DMAC7.html)
EP (1) EP1032399A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003535015A (cg-RX-API-DMAC7.html)
KR (1) KR100581308B1 (cg-RX-API-DMAC7.html)
CN (1) CN1147301C (cg-RX-API-DMAC7.html)
AR (1) AR013981A1 (cg-RX-API-DMAC7.html)
AU (1) AU742166C (cg-RX-API-DMAC7.html)
BR (1) BR9813262A (cg-RX-API-DMAC7.html)
CA (2) CA2649671A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0004133A3 (cg-RX-API-DMAC7.html)
IL (1) IL135742A (cg-RX-API-DMAC7.html)
MX (1) MXPA00003972A (cg-RX-API-DMAC7.html)
MY (1) MY121743A (cg-RX-API-DMAC7.html)
NO (1) NO326856B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ504066A (cg-RX-API-DMAC7.html)
PE (1) PE121799A1 (cg-RX-API-DMAC7.html)
RO (1) RO121319B1 (cg-RX-API-DMAC7.html)
RU (2) RU2261099C2 (cg-RX-API-DMAC7.html)
WO (1) WO1999020282A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529494A (ja) * 1998-11-18 2002-09-10 フェリング ベスローテン フェンノートシャップ プロゲステロン含有経膣投与用錠剤およびその調製法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
NZ591627A (en) * 2001-12-05 2012-09-28 Teva Womens Health Inc Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
AU2003239869A1 (en) * 2002-05-23 2003-12-12 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
AU2003297534A1 (en) * 2002-12-24 2004-07-22 Ovion, Inc. Contraceptive device and delivery system
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
PL1635843T3 (pl) * 2003-06-25 2009-06-30 Bayer Schering Pharma Ag Hormonalna terapia zastępcza i leczenie depresji obejmujące dienogest
CA2771944A1 (en) * 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
EP1761231A1 (en) * 2004-06-07 2007-03-14 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
WO2007076144A2 (en) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
WO2007085020A2 (en) * 2006-01-20 2007-07-26 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
US8235047B2 (en) 2006-03-30 2012-08-07 Conceptus, Inc. Methods and devices for deployment into a lumen
KR20090029237A (ko) * 2006-06-02 2009-03-20 피어 트리 파머슈티칼스 인코포레이티드 위축성 질염을 치료하는 방법
GB0616444D0 (en) * 2006-08-18 2006-09-27 Reckitt Benckiser Nv Detergent composition
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
ES2648640T3 (es) 2008-02-04 2018-01-04 Ferring B.V. Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
RU2697369C1 (ru) * 2018-12-21 2019-08-13 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Способ дифференциальной диагностики функциональной гипоталамической аменореи на фоне стресса и энергетического дефицита
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN113288865B (zh) * 2021-06-28 2022-03-08 浙江仙琚制药股份有限公司 一种黄体酮阴道凝胶剂的制备方法
CN114983929A (zh) * 2022-05-16 2022-09-02 安徽万邦医药科技股份有限公司 一种稳定的黄体酮缓释凝胶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
USD345211S (en) 1992-04-06 1994-03-15 Columbia Laboratories, Inc. Dispensing vial for feminine hygiene products
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
USD375352S (en) 1994-03-14 1996-11-05 Columbia Laboratories, Inc. Dispensing vial for feminine hygiene products

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529494A (ja) * 1998-11-18 2002-09-10 フェリング ベスローテン フェンノートシャップ プロゲステロン含有経膣投与用錠剤およびその調製法

Also Published As

Publication number Publication date
RU2330667C2 (ru) 2008-08-10
NZ504066A (en) 2002-11-26
US6593317B1 (en) 2003-07-15
HUP0004133A3 (en) 2001-09-28
KR100581308B1 (ko) 2006-05-22
RU2261099C2 (ru) 2005-09-27
RU2005101612A (ru) 2006-07-10
IL135742A (en) 2004-09-27
CA2649671A1 (en) 1999-04-29
WO1999020282A1 (en) 1999-04-29
MXPA00003972A (es) 2004-04-21
CA2307615A1 (en) 1999-04-29
AU742166C (en) 2005-07-14
AU1191499A (en) 1999-05-10
CN1147301C (zh) 2004-04-28
NO20002084L (no) 2000-06-21
NO326856B1 (no) 2009-03-02
AU742166B2 (en) 2001-12-20
US6306914B1 (en) 2001-10-23
HUP0004133A2 (hu) 2001-05-28
KR20010031299A (ko) 2001-04-16
US20010031747A1 (en) 2001-10-18
CN1282250A (zh) 2001-01-31
AR013981A1 (es) 2001-01-31
BR9813262A (pt) 2000-08-22
RO121319B1 (ro) 2007-03-30
PE121799A1 (es) 1999-12-17
EP1032399A1 (en) 2000-09-06
NO20002084D0 (no) 2000-04-19
IL135742A0 (en) 2001-05-20
MY121743A (en) 2006-02-28

Similar Documents

Publication Publication Date Title
US6593317B1 (en) Progestin therapy for maintaining amenorrhea
CA2171939C (en) Novel method of progesterone delivery and affect thereof
AU2010339867B2 (en) Nestorone/estradiol transdermal gel
RU2000112650A (ru) Прогестинотерапия с регулируемым кровотечением
JP2003048836A (ja) 効能を保持し無月経を引き起こす超低用量の経口避妊薬
Murray Natural progesterone: what role in women’s health care
JP2001523639A (ja) プロゲストゲン−抗プロゲストゲンレジメン
UA79421C2 (en) Progestin therapy with regular menstrual bleeding
AU689133C (en) Novel method of progesterone delivery and affect thereof
JP2007197459A (ja) 月経の出血を少なくし維持された効力を持つ超低投与量避妊薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080916

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100105